US 12,187,806 B2
Anti-CD73 antibodies and use thereof
Chun-Chung Lee, Taipei (TW); Yu-Hsun Lo, Taipei (TW); Chu-Bin Liao, Taipei (TW); Chen-Jei Hong, Taipei (TW); Sih-Yu Chen, Taipei (TW); Yen-Yu Wu, Taipei (TW); Szu-Liang Lai, Taipei (TW); Chih-Yung Hu, Taipei (TW); Wen-Bin Ke, Taipei (TW); Ya-Ting Juan, Taipei (TW); and Kao-Jean Huang, Taipei (TW)
Assigned to DEVELOPMENT CENTER FOR BIOTECHNOLOGY, New Taipei (TW)
Filed by Development Center for Biotechnology, New Taipei (TW)
Filed on Mar. 4, 2022, as Appl. No. 17/686,666.
Prior Publication US 2023/0279139 A1, Sep. 7, 2023
Int. Cl. C07K 16/28 (2006.01); A61K 39/395 (2006.01); A61K 45/06 (2006.01); A61P 35/00 (2006.01); A61K 39/00 (2006.01)
CPC C07K 16/2896 (2013.01) [A61K 39/39558 (2013.01); A61K 45/06 (2013.01); A61P 35/00 (2018.01); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01); C07K 2317/34 (2013.01); C07K 2317/622 (2013.01); C07K 2317/75 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01)] 33 Claims
 
1. An antibody or antigen-binding fragment thereof comprising:
a heavy chain variable domain comprising a HCDR1 region, a HCDR2 region and a HCDR3 region, wherein the HCDR1 region comprises the amino acid sequence of SEQ ID NO: 4; the HCDR2 region comprises the amino acid sequence of SEQ ID NO: 5; and the HCDR3 region comprises the amino acid sequence of SEQ ID NO: 6; and
a light chain variable domain comprising a LCDR1 region, a LCDR2 region and a LCDR3 region, wherein the LCDR1 region comprises the amino acid sequence of SEQ ID NO: 7, the LCDR2 region comprises the amino acid sequence of SEQ ID NO: 8, and the LCDR3 region comprises the amino acid sequence of SEQ ID NO: 9 or the amino acid sequence of SEQ ID NO: 9 with substitution of leucine residue at position 8 by methionine, glycine, histidine, arginine, glutamine or isoleucine,
wherein the antibody or antigen-binding fragment thereof binds to CD73 on at least one of the glutamic acid residue at position 296 and the arginine residue at position 297.